Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Phillips

Showing results (101-110 of 287) with videos related to

Pageof 29
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|September 26, 2009
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapyAnna Maria Geretti, Zoe V Fox, Clare L Booth, et al.
The Lancet. Global Health|March 26, 2021
The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysisAndrew N Phillips, Loveleen Bansi-Matharu, Valentina Cambiano, et al.
The Journal of Infectious Diseases|April 4, 2002
Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) studyAlessandro Cozzi-Lepri, Andrew N Phillips, Antonella d'Arminio Monforte, et al.
Antiviral Therapy|May 14, 2003
Changes in viral load in people with virological failure who remain on the same HAART regimenAlessandro Cozzi-Lepri, Andrew N Phillips, Veronica Miller, et al.
Sexually Transmitted Infections|January 12, 2021
Opposing associations of depression with sexual behaviour: implications for epidemiological investigation among gay, bisexual and other men who have sex with menAda R Miltz, Alison J Rodger, Andrew N Phillips, et al.
Vaccine|March 21, 2019
Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South AfricaChristian Selinger, Anna Bershteyn, Dobromir T Dimitrov, et al.
The Journal of Infectious Diseases|October 23, 2004
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapyColette J Smith, Caroline A Sabin, Mike S Youle, et al.
AIDS (London, England)|June 4, 2008
Stability of antiretroviral regimens in patients with viral suppressionRebecca K Lodwick, Colette J Smith, Mike Youle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 9, 2006
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across EuropeWendy P Bannister, Ole Kirk, Jose M Gatell, et al.
AIDS (London, England)|September 22, 2007
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitorsZoe V Fox, Anna Maria Geretti, Jesper Kjaer, et al.
Pageof 29

Showing results (101-110 of 287) with videos related to

Sort By:
Pageof 29
Journal of Acquired Immune Deficiency Syndromes (1999)|September 26, 2009
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapyAnna Maria Geretti, Zoe V Fox, Clare L Booth, et al.
The Lancet. Global Health|March 26, 2021
The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysisAndrew N Phillips, Loveleen Bansi-Matharu, Valentina Cambiano, et al.
The Journal of Infectious Diseases|April 4, 2002
Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) studyAlessandro Cozzi-Lepri, Andrew N Phillips, Antonella d'Arminio Monforte, et al.
Antiviral Therapy|May 14, 2003
Changes in viral load in people with virological failure who remain on the same HAART regimenAlessandro Cozzi-Lepri, Andrew N Phillips, Veronica Miller, et al.
Sexually Transmitted Infections|January 12, 2021
Opposing associations of depression with sexual behaviour: implications for epidemiological investigation among gay, bisexual and other men who have sex with menAda R Miltz, Alison J Rodger, Andrew N Phillips, et al.
Vaccine|March 21, 2019
Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South AfricaChristian Selinger, Anna Bershteyn, Dobromir T Dimitrov, et al.
The Journal of Infectious Diseases|October 23, 2004
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapyColette J Smith, Caroline A Sabin, Mike S Youle, et al.
AIDS (London, England)|June 4, 2008
Stability of antiretroviral regimens in patients with viral suppressionRebecca K Lodwick, Colette J Smith, Mike Youle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 9, 2006
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across EuropeWendy P Bannister, Ole Kirk, Jose M Gatell, et al.
AIDS (London, England)|September 22, 2007
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitorsZoe V Fox, Anna Maria Geretti, Jesper Kjaer, et al.
Pageof 29